CTIS2023-503659-88-00招募中1 期
J1I-MC-GZBM: A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3) - J1I-MC-GZBM
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 1,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Have obesity., Have established heart disease., Have history of unsuccessful dietary weight loss effort
排除标准
- •have had the following within 90 days before screening: heart attack, stroke, a procedure to get blood flowing back into the heart, or been hospitalized for either congestive heart failure or sudden chest pain because of a blood clot in the heart, Have been taking weight loss drugs, including over-the-counter medications, within 90 days before screening, Have a self-reported change in body weight greater than 11 pounds within 90 days before screening., have undergone weight loss surgery (e.g. stomach stapling, lap banding) within 1 year before screening, Have Type 1 diabetes, Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2), Have had chronic or acute pancreatitis
研究者
相似试验
招募中
1 期
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES)CTIS2023-508630-34-00Eli Lilly & Co.10,000
招募中
1 期
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)Type 2 DiabetesCTIS2023-507280-18-00Eli Lilly & Co.520
进行中（未招募）
1 期
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)Overweight, Obesity, Type 2 DiabetesCTIS2022-502837-24-00Eli Lilly & Co.1,460
进行中（未招募）
1 期
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)Obesity, Overweight, Overweight or ObesityCTIS2022-502839-19-00Eli Lilly & Co.3,000
招募中
1 期
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesCTIS2023-504583-42-00Eli Lilly & Co.120